Table 1. Studies assessing MET mutations in sarcomatoid carcinoma.
| Study | Number of pts N= | Histological Subtypes of SC | Controls N= | MET ex 14 analysis | MET ex 14 frequency in SC N (%) | MET ex 14 frequency in controls N (%) |
|---|---|---|---|---|---|---|
| Saffroy et al 2016 | 81 | PC (77.8%) Others (22.2%) | ADC (N=150) | Whole met ex 14 and flanking intronic regions (14 +/− n bp)MassArray and HRMParaffin embedded tumors | 4 (4.9%) | 8 (5.3%) |
| Schrock et al 2016 | 104 | PC and others | NSCLC (N=11 101) includingADC (N=7140) | NGS - Capture hybrydization including intronic regionsParaffin embedded tumors | 8 (7.7%) | NSCLC : 290 (2.14%)ADC : 205 (2.8%) |
| Tong et al 2016 | 22 | ND | NSCLC (N=665) including ADC (N=392) | Whole met ex 14 and flanking intronic regions (14 +/− n bp) Sanger sequencingParaffin embedded tumors | 7 (31.8 %) | NSCLC : 1 (0.3%)ADC : 10 (2.6%) |
| Awad et al 2016 | 15 | ND | NSLC (N=1126) including ADC (N=873) | NGS (22 genes) | 4 (26.7%) | NSCLC : 6 (2.4%)ADC : 18 (2.1%) |
| Liu et al2015 | 36 | ND carcinosarcoma and blastoma excluded | Not studied | Whole-exome sequencingTargeting exome sequencing (Truseq panel, Illumina) Sanger sequencing half frozen & half paraffin embedded tumors | 8 (22%) | Not studied |
| Vieira et al 2014 | 77 | PC (78%) Others (22%) | Not studied | Sizing analysis of fluorescently labeled PCR products (only 3′-splice site of MET ex 14 deletions) Formalin-fixed paraffin-embedded samples | 2 (3%) | Not studied |
Pts : patients; SC : sarcomatoid carcinomas; ADC : adenocarcinoma, NSCLC : non small lung carcinoma; PC: pleomorphic carcinoma; ND : Not described; CGP : comprehensive genomic profiling; NGS: next-generation sequencing; ex : exon;